Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post

Vivimed Labs Ltd: Intrinsic Value & Share Price Analysis

Fair Value

₹46.63Undervalued by 611.91%vs CMP ₹6.55

P/E (15.0) × ROE (15.0%) × BV (₹25.40) × DY (2.00%)

Defaults: P/E=15, ROE=15%

₹44.63Undervalued by 581.37%vs CMP ₹6.55
MoS: +85.3% (Strong)Confidence: 28/100 (Low)Models: 1 Under, 1 Fair
ModelCategoryValueWeightSignal
PE-ROEEarnings₹67.2163%Under (+926.1%)
Revenue MultipleRevenue₹7.0038%Fair (+6.9%)
Consensus (2 models)₹44.63100%Undervalued
Key Drivers: EPS CAGR 44.1% lifts DCF — verify sustainability.

PE-ROE · Graham · EPV · DCF · NAV · EV/EBITDA · DDM · Earnings Yield · ROCE Capital · Revenue Multiple | CoE: 12% · Terminal: 4% · EPS CAGR: 44.1% · Defaults: P/E=15, ROE=15%

*Investments are subject to market risks

Analyst Summary

Vivimed Labs Ltd operates in the Pharmaceuticals segment, NSE: VIVIMEDLAB | BSE: 532660, current market price is ₹6.55, market cap is 54.3 Cr.. At a glance, ROE is %, ROCE is 65.2 %, book value is 25.4, dividend yield is 0.00 %. The latest intrinsic value estimate is ₹44.63, which is about 581.4% above the current price, so the page currently reads as potentially undervalued rather than fully priced. On operating trend, latest reported sales are about ₹116 Cr versus the prior period change of -22.1%, while latest net profit is about ₹-32 Cr with a prior-period change of 28.9%. The 52-week range shown on this page is 29.4/4.75, which helps frame where the current quote sits within its recent trading band. Business context: About the Company - Qualitative AnalysisVivimed Labs Ltd. is a Public Limited Listed company incorporated on 22/09/1988 and has its registered office in the State of Karnataka, India. Company's Corporate Identification Number(CIN) is L02411…

This summary is generated from the stock page data available for Vivimed Labs Ltd: Intrinsic Value & Share Price Analysis and is refreshed automatically when the underlying metrics change.

Investment Snapshot

53
Vivimed Labs Ltd scores 53/100 (Average)
Based on 5 dimensions: health, institutional flow, earnings quality, momentum, and peer comparison
Stock Health46/100 · Moderate
ROCE 65.2% ExcellentROE 0.0% WeakD/E 0.64 ModerateInterest Coverage 0.0x RiskyProfitable 0/5 years Inconsistent
Smart Money50/100 · Moderate
FII holding stable No changePromoter holding at 7.6% Stable
Earnings Quality75/100 · Strong
OPM expanding (-52% → -17%) ImprovingWorking capital: -255 days (improving) Efficient
Quarterly Momentum35/100 · Weak
Revenue (4Q): -22% YoY Declining
Industry Rank55/100 · Moderate
ROCE 65.2% vs industry 25.3% Above peers3Y sales CAGR: -21% Shrinking

Weights: Health 30% · Earnings Quality 25% · Momentum 20% · Industry Rank 15% · Smart Money 10%. Scores are computed from reported financials and recalculated daily.

Share Price and Basic Stock Data

Last Updated: August 25, 2026, 8:47 am

Market Cap 54.3 Cr.
Current Price 6.55
Intrinsic Value₹44.63
High / Low 29.4/4.75
Stock P/E
Book Value 25.4
Dividend Yield0.00 %
ROCE65.2 %
ROE%
Face Value 2.00
PEG Ratio0.00

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Vivimed Labs Ltd

Competitors

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Lactose (India) Ltd 125 Cr. 99.0 137/76.018.0 51.50.00 %11.3 %9.81 % 10.0
MPS Pharmaa Ltd 3.80 Cr. 1.99 2.08/1.57 0.040.00 %13.1 %177 % 10.0
Gujarat Themis Biosyn Ltd 4,415 Cr. 405 479/22590.7 26.40.16 %17.9 %17.4 % 1.00
Gujarat Terce Laboratories Ltd 27.8 Cr. 35.7 59.8/29.012.5 12.50.00 %39.2 %30.2 % 10.0
Gujarat Inject (Kerala) Ltd 168 Cr. 11.5 14.3/1.9056.2 0.810.00 %22.9 %16.6 % 1.00
Industry Average23,072.45 Cr1,307.3954.56215.820.36%25.34%18.37%6.02

All Competitor Stocks of Vivimed Labs Ltd

Quarterly Result

MetricSep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025
Sales 44.2255.7437.0335.3533.6441.4638.6229.3724.7736.5125.6121.3920.61
Expenses 53.5360.87201.3235.6839.5440.1967.0940.3725.4135.4628.0821.6721.56
Operating Profit -9.31-5.13-164.29-0.33-5.901.27-28.47-11.00-0.641.05-2.47-0.28-0.95
OPM % -21.05%-9.20%-443.67%-0.93%-17.54%3.06%-73.72%-37.45%-2.58%2.88%-9.64%-1.31%-4.61%
Other Income 0.150.050.680.112.200.047.630.060.030.074.220.380.21
Interest 8.859.228.5210.6611.8913.21-33.330.300.430.481.740.581.66
Depreciation 4.024.0295.924.704.704.705.844.014.106.625.505.014.90
Profit before tax -22.03-18.32-268.05-15.58-20.29-16.606.65-15.25-5.14-5.98-5.49-5.49-7.30
Tax % 0.00%0.00%-0.77%0.00%0.00%-3.31%20.90%0.00%0.00%0.00%2.19%0.00%0.00%
Net Profit -22.03-18.31-265.99-15.58-20.30-16.055.26-15.25-5.14-5.98-5.60-5.49-7.30
EPS in Rs -2.66-2.21-32.08-1.88-2.45-1.940.63-1.84-0.62-0.72-0.68-0.66-0.88

Last Updated: March 3, 2026, 1:50 pm

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 26, 2026, 10:16 am

MetricMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales 1,3511,3801,3461,4621,1861,3151,059861237187149116104
Expenses 1,1391,1561,1111,0579711,1351,049830245374182129107
Operating Profit 2122242344042151801032-8-187-33-13-3
OPM % 16%16%17%28%18%14%1%4%-3%-100%-22%-11%-3%
Other Income 861181023810111045
Interest 67868468827061564036334
Depreciation 666661585667675618108202022
Profit before tax 87781002868666-109-70-65-331-46-32-24
Tax % 24%7%16%25%11%13%-0%3%4%-1%-1%0%
Net Profit 6672842147657-109-72-68-329-45-32-24
EPS in Rs 8.208.9010.3326.419.446.95-13.16-8.67-8.16-39.62-5.48-3.85-2.94
Dividend Payout % 7%-0%-0%2%4%-0%-0%-0%-0%-0%-0%-0%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)9.09%16.67%154.76%-64.49%-25.00%-291.23%33.94%5.56%-383.82%86.32%28.89%
Change in YoY Net Profit Growth (%)0.00%7.58%138.10%-219.25%39.49%-266.23%325.17%-28.39%-389.38%470.15%-57.43%

Vivimed Labs Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:-22%
5 Years:-36%
3 Years:-21%
TTM:-24%
Compounded Profit Growth
10 Years:%
5 Years:11%
3 Years:15%
TTM:52%
Stock Price CAGR
10 Years:-21%
5 Years:-25%
3 Years:-20%
1 Year:%
Return on Equity
10 Years:%
5 Years:%
3 Years:%
Last Year:%

Last Updated: September 5, 2025, 1:51 pm

Balance Sheet

Last Updated: July 28, 2026, 4:00 am

MonthMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital 161616171717171717171717
Reserves 47950571888560249341534823-22-52-227
Borrowings 1,0761,0151,0111,1491,2801,268326359379377376397
Other Liabilities 327519317343431432532543658579580567
Total Liabilities 1,8982,0552,0622,3942,3292,2101,2891,2661,076950921753
Fixed Assets 8138148791,0359651,045502520436418408386
CWIP 9094766512289604021211718
Investments 3333386199199199168168181
Other Assets 9921,1441,1041,2901,239990529507421343328170
Total Assets 1,8982,0552,0622,3942,3292,2101,2891,2661,076950921753

Reserves and Borrowings Chart

Cash Flow

MonthMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity + 1401545821422805672835-24-28
Cash from Investing Activity + -107-190-68-164-89-196404-16-528-5-1
Cash from Financing Activity + -424135186-33872-1,015-10-34-65-6
Net Cash Flow -842544-5-44-441-3-2-11
Free Cash Flow 1695-11-142333-331,0841130-26-67
CFO/OP 63%66%23%30%243%972%1,720%-352%-19%73%13%-5%

Free Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Free Cash Flow212.00223.00233.00403.00214.00179.009.00-294.00-367.00-566.00-410.00-389.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days 9487885085998646134145203233
Inventory Days 249244294329411397396263573216327358
Days Payable 106107981221542071793510074225240
Cash Conversion Cycle 237224285258342288303274607286305351
Working Capital Days 574358551216821677195-15-171-255
ROCE %12%11%12%22%9%7%-3%-1%-3%-52%-9%-8%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthJun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Promoters 20.94%20.94%20.94%20.94%20.94%20.94%20.94%20.94%7.76%7.76%7.76%7.57%
FIIs 1.64%1.64%1.64%1.64%1.64%1.64%1.64%1.64%1.64%1.64%1.64%1.64%
Government 0.12%0.12%0.12%0.12%0.12%0.12%0.12%0.12%0.12%0.12%0.12%0.12%
Public 77.30%77.29%77.30%77.29%77.30%77.30%77.30%77.30%90.47%90.47%90.47%90.66%
No. of Shareholders 49,50349,03849,02749,01649,01249,00349,00548,95748,92848,92549,22147,492

Shareholding Pattern Chart

No. of Shareholders

Vivimed Labs Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

This stock is not held by any mutual fund.

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 25Mar 24Mar 23Mar 22Mar 21
FaceValue 2.002.002.002.002.00
Basic EPS (Rs.) -3.85-5.48-39.62-8.16-8.67
Diluted EPS (Rs.) -3.74-5.32-39.62-7.92-8.42
Cash EPS (Rs.) -1.42-3.08-26.55-5.95-1.98
Book Value[Excl.RevalReserv]/Share (Rs.) -8.82-5.240.1739.3547.47
Book Value[Incl.RevalReserv]/Share (Rs.) -4.24-0.654.7543.9352.05
Revenue From Operations / Share (Rs.) 14.0217.9822.5728.62103.90
PBDIT / Share (Rs.) -1.05-2.13-22.47-0.814.77
PBIT / Share (Rs.) -3.49-4.53-35.55-3.02-1.93
PBT / Share (Rs.) -3.84-4.82-39.88-7.82-8.43
Net Profit / Share (Rs.) -3.85-5.48-39.62-8.16-8.67
NP After MI And SOA / Share (Rs.) -3.85-5.48-39.62-8.16-8.67
PBDIT Margin (%) -7.46-11.82-99.59-2.864.58
PBIT Margin (%) -24.85-25.19-157.53-10.56-1.85
PBT Margin (%) -27.39-26.82-176.72-27.32-8.10
Net Profit Margin (%) -27.48-30.48-175.59-28.50-8.34
NP After MI And SOA Margin (%) -27.48-30.48-175.59-28.50-8.34
Return on Networth / Equity (%) 0.000.00-23087.35-20.73-18.26
Return on Capital Employeed (%) -5.63-6.94-52.25-2.80-1.68
Return On Assets (%) -3.47-4.77-33.24-5.34-5.57
Long Term Debt / Equity (X) -0.86-1.4643.790.180.14
Total Debt / Equity (X) -5.14-8.67266.031.100.64
Asset Turnover Ratio (%) 0.120.150.160.180.12
Current Ratio (X) 0.800.830.781.361.55
Quick Ratio (X) 0.650.670.590.710.80
Inventory Turnover Ratio (X) 1.891.251.170.570.24
Interest Coverage Ratio (X) -2.94-7.25-5.19-0.170.73
Interest Coverage Ratio (Post Tax) (X) -9.85-15.29-8.15-0.70-0.33
Enterprise Value (Cr.) 0.000.00430.11471.51378.03
EV / Net Operating Revenue (X) 0.000.002.301.990.43
EV / EBITDA (X) 0.000.00-2.31-69.449.57
MarketCap / Net Operating Revenue (X) 0.000.000.290.500.15
Price / BV (X) 0.000.0038.870.360.33
Price / Net Operating Revenue (X) 0.000.000.290.500.15
EarningsYield 0.000.00-5.94-0.56-0.54

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

[display_about_company_data title=”About the Company – Qualitative Analysis”]

FAQ

What is the intrinsic value of Vivimed Labs Ltd and is it undervalued?

As of 07 September 2026, Vivimed Labs Ltd's intrinsic value is ₹44.63, which is 581.37% higher than the current market price of ₹6.55, suggesting the stock is undervalued. This is calculated using the PE ratio method factoring in ROE (%), book value (₹25.4), dividend yield (0.00 %), and 5-year EPS CAGR.

What is the current share price and 52-week range of Vivimed Labs Ltd?

Vivimed Labs Ltd is trading at ₹6.55 as of 07 September 2026, with a FY2026-2027 high of ₹29.4 and low of ₹4.75. The stock is currently near its 52-week low. Market cap stands at ₹54.3 Cr..

How does Vivimed Labs Ltd's P/E ratio compare to its industry?

Vivimed Labs Ltd has a P/E ratio of , which is below the industry average of 54.56. This is broadly in line with or below the industry average.

Is Vivimed Labs Ltd financially healthy?

Key indicators for Vivimed Labs Ltd: ROCE of 65.2 % indicates efficient capital utilization; ROE of % is below ideal levels (industry average: 18.37%). Dividend yield is 0.00 %.

Is Vivimed Labs Ltd profitable and how is the profit trend?

Vivimed Labs Ltd reported a net profit of ₹-32 Cr in Mar 2025 on revenue of ₹116 Cr. Compared to ₹-68 Cr in Mar 2022, the net profit shows a mixed trend.

Does Vivimed Labs Ltd pay dividends?

Vivimed Labs Ltd has a dividend yield of 0.00 % at the current price of ₹6.55. The company is currently not paying meaningful dividends.

Last Updated: August 25, 2026, 8:47 am
Author: Getaka|Social: XLinkedIn
Stock Ticker - BSE: 532660 | NSE: VIVIMEDLAB
Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Vivimed Labs Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Explore Industry-wise Stock Analysis Reports